Stanford Medicine researchers have identified a primary driver of biological aging: the failure of tissue-resident macrophages to clear senescent, or “zombie,” neutrophils from the body. According to a study published July 16 in Science, blocking a specific pro-inflammatory receptor, EP2, on these immune cells rejuvenated organ function and reduced age-related frailty in mice. This discovery suggests a potential pharmaceutical pathway to extend human health spans by targeting systemic inflammation at its cellular source.
The Role of Neutrophils in Biological Aging
Neutrophils are the immune system’s first responders, but they are remarkably short-lived. Most survive less than 24 hours before they are slated for disposal. According to Katrin Andreasson, MD, professor in neurology and neurological sciences at Stanford Medicine, approximately 100 billion neutrophils are produced daily. In a healthy state, tissue-resident macrophages act as the body’s garbage collectors, consuming these cells once they reach the end of their lifecycle.
However, as organisms age, these neutrophils often enter a senescent state rather than dying off cleanly. Instead of being cleared, these “zombie” cells release toxic chemicals that damage neighboring tissues. Andreasson notes that senescent neutrophils are essentially “killing our tissues,” contributing to the chronic, low-grade inflammation that characterizes the aging process.
Did you know?
Macrophages are versatile immune cells that function as soldiers, builders, and medics. They inhabit specific organs during fetal development and remain there for the duration of an organism’s life to maintain local tissue health.
How the EP2 Receptor Accelerates Senescence
The accumulation of senescent cells is driven by a signaling breakdown involving the hormone prostaglandin E2 (PGE2). While PGE2 has various roles in the body, its interaction with the EP2 receptor on macrophages is specifically pro-inflammatory. As organisms age, both PGE2 levels and the concentration of EP2 receptors on macrophages increase.
This creates a feedback loop: the persistent stimulation of EP2 prevents macrophages from effectively engulfing and digesting dead or dying neutrophils. The research, led by instructor Jessy Tan, PhD, demonstrates that when this receptor is either genetically removed or blocked by an experimental drug, the “garbage collection” function of the macrophages is restored. This prevents the buildup of senescent neutrophils and the subsequent inflammatory damage to organs including the liver, heart, and brain.
Restoring Youthful Function Through EP2 Inhibition
In experiments involving older mice—equivalent to humans in their 60s or 70s—the removal of the EP2 receptor led to systemic improvements. Researchers observed that mice lacking the receptor remained leaner, maintained greater muscle mass, and showed improved cognitive performance in maze tests compared to control groups.
The study identified 71 proteins in the blood that are altered by age; 59 of those proteins returned to youthful levels in the mice with deactivated EP2 receptors. Importantly, the researchers treated 22-month-old mice with an experimental EP2-inhibiting drug for two months, which successfully reduced senescent neutrophil counts and restored macrophage function. Andreasson emphasizes that while current non-steroidal anti-inflammatory drugs (NSAIDs) block PGE2 production, they often disrupt other vital biological processes. The goal for future clinical applications is to develop a targeted drug that specifically incapacitates EP2 without affecting the broader, beneficial functions of prostaglandins.
Frequently Asked Questions
- What are senescent neutrophils?
These are short-lived immune cells that fail to die properly, instead entering a “zombie” state where they release toxic chemicals that inflame and damage surrounding tissues. - What is the function of tissue-resident macrophages?
These long-lived cells reside in specific organs to perform maintenance, including the vital task of clearing away dead or senescent cells like neutrophils. - Could this lead to anti-aging drugs for humans?
The study indicates that blocking the EP2 receptor can rejuvenate organ function in mice. Researchers are now looking to develop safe, selective drugs that target this receptor in humans to potentially extend health spans.
Current anti-inflammatory medications like aspirin act broadly by blocking PGE2 production. Future therapies aim for precision, targeting only the EP2 receptor to avoid the side effects associated with systemic prostaglandin inhibition.
For more updates on medical breakthroughs and the latest in longevity research, subscribe to our weekly newsletter or explore our archive of biotech and health innovation articles.
Worth a look